GBA Gene Therapy is an emerging experimental approach for treating Parkinson's disease (PD) in patients with GBA mutations. The glucocerebrosidase (GCase) enzyme, encoded by the GBA gene, plays a critical role in lysosomal function, and mutations in GBA represent one of the most significant genetic risk factors for PD.
¶ GBA Mutations and Parkinson's Disease
- 10-15% of PD patients carry GBA mutations
- GBA mutations increase PD risk 5-6 fold in heterozygotes
- Associated with earlier onset and more severe cognitive symptoms
- GBA is the most common genetic risk factor for PD aside from LRRK2 and SNCA
The glucocerebrosidase enzyme (GCase) is responsible for breaking down glucosylcer lysamide inosomes. Loss of GCase function leads to:
- Glucosylceramide accumulation in lysosomes
- Lysosomal dysfunction and impaired autophagy
- α-Synuclein aggregation (GCase regulates SNCA clearance)
- Mitochondrial dysfunction
- Endoplasmic reticulum stress
- Recombinant GCase delivery to increase enzymatic activity
- Limitations: Cannot cross the blood-brain barrier
- Currently only approved for Gaucher disease, not PD
- AAV9 serotype preferentially targets neurons
- Delivers functional GBA1 gene
- Promoters: Synapsin (neuronal), GFAP (astrocytic)
- Clinical trials in planning stages
- Used in preclinical studies
- Provides long-term expression
- Safety concerns about insertional mutagenesis
Pharmacological chaperones stabilize mutant GCase and promote proper folding:
| Drug | Company | Status | Mechanism |
|------|---------|--------|-----------|
| Migalastat (Galafold) | Amicus | Approved for Fabry/Gaucher | Oral small molecule chaperone |
| Ambroxol | Various | Clinical trials (PD) | Secretory chaperone, increases GCase |
| Venglustat (GZ161) | Sanofi | Discontinued | Substrate reduction therapy |
- Venglustat (GZ/SAR402671) reduces glucosylceramide substrate
- Aims to compensate for reduced GCase activity
- Clinical trials for PD with GBA mutations
- In vivo gene editing approaches being developed
- Corrects GBA mutations in the brain
- Challenges: Delivery across blood-brain barrier
- Preclinical stages
| Trial |
Phase |
Intervention |
Status |
| ambroxol-PD |
Phase II |
Ambroxol (GCase enhancer) |
Recruiting |
| GBA-PD Natural History |
Observational |
N/A |
Recruiting |
- Blood-brain barrier - vectors must cross BBB
- Delivery - targeting specific brain regions (substantia nigra)
- Expression levels - balancing therapeutic vs. toxic overexpression
- Immunogenicity - immune response to viral vectors
- Patient selection - identifying GBA mutation carriers
- Restore GCase activity in neurons and glia
- Reduce glucosylceramide accumulation
- Improve lysosomal function
- Enhance α-synuclein clearance
- Protect dopaminergic neurons
- Gba1 knockout mice: Show increased α-synuclein aggregation
- AAV-GBA delivery: Reduces α-synuclein in mouse models
- Combination therapy: GBA + SNCA knockdown shows synergy
- iPSC-derived neurons from GBA PD patients
- Gene therapy rescues lysosomal deficits
- Reduces pathological α-synuclein
| Target |
Approach |
Delivery |
Status |
| AADC |
Enzyme replacement |
AAV |
Approved |
| GBA |
Gene therapy/chaperone |
AAV/small molecule |
Phase II |
| LRRK2 |
Kinase inhibitor |
Small molecule |
Phase III |
| SNCA |
ASO/siRNA |
Antisense |
Phase I/II |
- Brain-targeted AAV vectors - improved BBB crossing
- Regulatable promoters - control expression levels
- Combination approaches - GBA + α-synuclein targeting
- Patient stratification - GBA mutation carriers only
- Early intervention - prodromal PD patients
- Will gene therapy work in sporadic PD?
- What is the optimal delivery method?
- How long will therapeutic effects last?
- Can this prevent cognitive decline in GBA-PD?
- Glucocerebrosidase and Parkinson's disease - Reviews GBA-PD connection
- AAV-GBA gene therapy for PD - Preclinical proof of concept
- Ambroxol for PD trial - Phase II trial design
- Substrate reduction therapy in PD - Venglustat development
See also: Gene Therapy, AAV Vectors, Parkinson's Disease